# Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

> **NCT01981811** · PHASE2 · WITHDRAWN · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.**

## Conditions studied

- Bipolar 1 Disorder
- Schizophrenia
- Mental Disorder
- Nervous System Diseases

## Interventions

- **DRUG:** Aripiprazole
- **DEVICE:** Ingestible Event Marker (IEM)

## Key facts

- **NCT ID:** NCT01981811
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-03
- **Primary completion:** 2014-05
- **Final completion:** 2014-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial was terminated because it was determined that the usability of the MIND1 System in the intended population was necessary before conducting this trial.
- **Last updated:** 2015-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01981811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01981811, "Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01981811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*